Wexford Capital’s Abeona Therapeutics ABEO Stock Holding History

Wexford Capital’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,064	Closed	-$42K	–	192
2020 Q4	$42K	Buy	+1,064	New	+$36.2K	0.01%	208

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wexford Capital's ABEO Position: Q1 2021 in Review

Wexford Capital sold out of Abeona Therapeutics (ABEO) in Q1 2021, closing a stake of 1,064 shares — an estimated $42K sold.

Wexford Capital first reported a position in ABEO in Q4 2020 and held it in 1 quarter. The position peaked at $42K in Q4 2020. 75 funds tracked by Wall St. Rank hold ABEO as of Q1 2021.

Wexford Capital reported no remaining Abeona Therapeutics position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 1,064 Abeona Therapeutics shares in Q1 2021, an estimated $42K.
Wexford Capital first reported a position in Abeona Therapeutics in Q4 2020 and held it in 1 quarter.
Wexford Capital's Abeona Therapeutics position peaked at $42K in Q4 2020.
75 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.